dapi ii counterstain (antifade/mount) (Abbott Laboratories)
Structured Review

Dapi Ii Counterstain (Antifade/Mount), supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/counterstained+in+dapi+ii+with+antifade/dapi+ii+counterstain/pmc06308247-124-237-241
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation"
Article Title: Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation
Journal: MethodsX
doi: 10.1016/j.mex.2018.11.015
Figure Legend Snippet: Interphase FISH analysis with probes generated by three different fragmentation methods. LAPC4 prostate cancer cells were subject to FISH analysis using probes prepared from non-overlapping BAC clones containing DNA sequences flanking the TMPRSS2 gene. Upstream BAC RP11-35C4 was labelled with green fluorophore and downstream BAC RP11-825A8 was labelled with red fluorophore. Nuclei were counterstained with DAPI. (A) FISH probes prepared by sonication. (B) FISH probes prepared using Fragmentase enzyme. (C) FISH probes prepared with restriction enzyme digestion using CviQ1/AluI.
Techniques Used: Generated, Clone Assay, Sonication
Related Articles
Fluorescence:Article Title: Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Article Snippet: The prognosis of patients with malignant glioma remains extremely poor, despite surgery and improvements in radioand chemo-therapies.. Nanotechnologies represent great promise in glioma therapy as they protect therapeutic agent and allow its sustained release.. However, new paradigms allowing tumor specific targeting and extensive intratumoral distribution must be developed to efficiently deliver nanoparticles (NPs). Microscopy:Article Title: Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Article Snippet: The prognosis of patients with malignant glioma remains extremely poor, despite surgery and improvements in radioand chemo-therapies.. Nanotechnologies represent great promise in glioma therapy as they protect therapeutic agent and allow its sustained release.. However, new paradigms allowing tumor specific targeting and extensive intratumoral distribution must be developed to efficiently deliver nanoparticles (NPs). |